Arndt Hartmann

Medicine · Health Sciences

20h-index9.0kcitations170works4.82yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(23), Urinary and Genital Oncology Studies(10), Genital Health and Disease(7), Epigenetics and DNA Methylation(6), Genetic factors in colorectal cancer(6)

Publications144 total

790 Current Reporting Trends, Practices, and Resource Utilization in Penile Cancer: A Survey among Genitourinary Pathologists
Laboratory Investigation·2025
854 Analysing the Spatial and Scale Heterogeneity of Muscle Invasive Bladder Cancer Molecular Subtypes
Laboratory Investigation·2025
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer
Nature Communications·2024· 16 citedOpen Access
High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trial
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin·2024· 7 citedOpen Access
Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) in Penile Squamous Cell Carcinoma—No Evidence for a Role in Carcinogenesis
Current Oncology·2024· 1 citedOpen Access
The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs—Part B: Prostate and Urinary Tract Tumors
European Urology·2022· 262 cited
Eine verminderte Knochendichte ist bei Patienten mit Zirrhose assoziiert mit Infektionen und Komplikationen aufgrund portaler Hypertension
Zeitschrift für Gastroenterologie·2021
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
Nature Communications·2021· 355 citedOpen Access
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†
European Urology·2020· 86 cited
An integrated multi-omics analysis identifies clinically relevant molecular subtypes of non-muscle-invasive bladder cancer
2020· 10 citedOpen Access
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5
European Urology·2020· 2 cited
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
European Urology·2019· 1.3k citedOpen Access
A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer
SSRN Electronic Journal·2019· 11 citedOpen Access
The consensus molecular classification of muscle-invasive bladder cancer
2018· 152 citedOpen Access
Molecular Markers Increase Precision of the European Association of Urology Non–Muscle-Invasive Bladder Cancer Progression Risk Groups
Clinical Cancer Research·2018· 91 cited
Welche Rolle spielt die Immunonkologie beim Urothelkarzinom aus pathologischer Sicht?
Aktuelle Urologie·2017
Prognostic Impact of a 12-gene Progression Score in Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study
European Urology·2017· 92 cited
Assessing Disease Activity in Crohn's Disease Using Multispectral Optoacoustic Tomography
Gastroenterology·2017
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
Cancer Cell·2016· 634 cited
Molekulare Klassifikation des Harnblasenkarzinoms: Mögliche Ähnlichkeit zum Mammakarzinom
Der Pathologe·2016
page 1 of 8Next →

Frequent Co-authors

Mike Recher(36), Karl S. Lang(36), Wolfgang Dietmaier(33), Alexander K. C. Leung(31), Cord Sunderkötter(31), William Lane M. Robson(26), Alexander K. C. Leung(26), Hans K. Biesalski(24), Naidu K. Akhilender(24), Armin Zittermann(24), Angelo Azzi(24), Yeşim Neğiş(24), Arie Markel(24), Nir Kfir(24), O Gressner(21), Stefan Beissert(19), Lee A. Denson(17), Dimitrios Samonakis(17), Andrew K. Burroughs(17), Ralf Kubitz(17)